Amnestic Mild Cognitive Impairment Clinical Trial
— CTA-MCIOfficial title:
The CTA-MCI Study: a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Control Training on Episodic Memory Function in Patients With Amnestic Mild Cognitive Impairment
This study evaluates the efficacy and mechanism of internet-based cognitive control training on episodic memory function in patients with amnestic Mild Cognitive Impairment(aMCI). Half of participants will receive adaptive internet-based cognitive control training program, while the other half will receive a fixed, primary difficulty level task.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | April 2020 |
Est. primary completion date | November 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility |
Inclusion Criteria: - Literate Chinese, aged 50 years and older - Complaint about memory loss and confirmed by an informant - Cognitive impairment in memory domain, adjusted for age and education - Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities - Clinical dementia rating (CDR) =0.5, Mini-Mental State Examination (MMSE) score = 20 (primary school) or = 24 (junior school or above) - Failure to meet the criteria for dementia Exclusion Criteria: - history of clinically significant stroke - neurological diseases that may lead to neurological distortion, including schizophrenia, severe anxiety or depression, frontotemporal dementia,Huntington disease, brain tumor, parking disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal pressure hydrocephalus - systemic diseases that may lead to neurological distortion, including hypothyroidism, folic acid deficiency, vitamin B12 deficiency, severe anemia, specific infection such as HIV and syphilis - clinically significant gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease; - cancer, alcoholism, drug addiction; - severe aphasia, physical disabilities, or any other factor that may preclude completion of neuropsychological testing; - use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents; - inability to undergo a brain MRI. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital, Zhejiang University | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | MoCA | The participants will be followed up 6 months after recruitment. The training is not mandatory after 12 weeks, but the training details will be acquired from the online system. | 6 months | |
Other | AVLT | The participants will be followed up 6 months after recruitment. The training is not mandatory after 12 weeks, but the training details will be acquired from the online system. | 6 months | |
Other | Gray matter volume | The participants will be followed up 6 months after recruitment. The training is not mandatory after 12 weeks, but the training details will be acquired from the online system. | 6 months | |
Other | White matter Integrity | The participants will be followed up 6 months after recruitment. The training is not mandatory after 12 weeks, but the training details will be acquired from the online system. | 6 months | |
Other | Functional connectivity across regions | The participants will be followed up 6 months after recruitment. The training is not mandatory after 12 weeks, but the training details will be acquired from the online system. | 6 months | |
Primary | Montreal Cognitive Assessment (MoCA) | The study uses MoCA to assess changes in the global cognitive function after an intervention of cognitive control training | 12 weeks | |
Primary | Auditory Verbal Learning Test (AVLT) | The study uses AVLT to assess changes in the episodic memory function after an intervention of cognitive control training | 12 weeks | |
Secondary | Gray matter volume | The study uses voxel-based morphometry (VBM) to measure changes of gray matter volume after an intervention of cognitive training. | 12 weeks | |
Secondary | White matter Integrity | The study uses Diffusion tensor imaging and tracking (DTI) to measure changes of the Integrity of white matter after an intervention of cognitive control training | 12 weeks | |
Secondary | Brain response change | The study uses task functional MRI (fMRI) to measure the brain response changes during the task after an intervention of cognitive control training | 12 weeks | |
Secondary | Functional connectivity across regions | The study uses resting state functional MRI(rs-fMRI) and task fMRI to measure changes of functional connectivity across regions after an intervention of cognitive control training | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01525368 -
Outcome Predictors of a Cognitive Intervention in aMCI
|
N/A | |
Completed |
NCT00785759 -
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
|
Phase 2 | |
Recruiting |
NCT05903573 -
Training Response Artificial Intelligence Network (TRAIN)
|
N/A | |
Completed |
NCT02562989 -
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
|
Phase 1 | |
Completed |
NCT02910739 -
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
|
Phase 1 | |
Completed |
NCT04185298 -
mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment
|
N/A | |
Not yet recruiting |
NCT04103463 -
Interactive Stepping Exercise on Memory
|
N/A | |
Recruiting |
NCT04063956 -
COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT
|
N/A | |
Terminated |
NCT01953601 -
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
|
Phase 3 | |
Recruiting |
NCT06041152 -
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
|
Phase 2 | |
Completed |
NCT01962038 -
A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT06444568 -
Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments
|
N/A | |
Not yet recruiting |
NCT05987007 -
Sleep Interventions and Neurocognitive Outcomes
|
N/A | |
Recruiting |
NCT04240561 -
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
|
N/A | |
Completed |
NCT01767909 -
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
|
Phase 2/Phase 3 | |
Terminated |
NCT01072812 -
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
|
Phase 1 | |
Completed |
NCT00643266 -
Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT04504630 -
Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury
|
N/A | |
Terminated |
NCT00582855 -
Effect of AQW051 in Patients With Memory Impairment
|
Phase 2 | |
Recruiting |
NCT05446584 -
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
|
Phase 2 |